Invivyd Says VYD222 (pemivibart), A Half-life Extended Investigational Monoclonal Antibody (mAb), Shows Continued In Vitro Neutralization Activity In Pseudovirus Assays Designed To Represent Predominant Emerging Variants Of SARS-CoV-2
Portfolio Pulse from Benzinga Newsdesk
Invivyd's investigational monoclonal antibody VYD222 shows continued in vitro neutralization activity against emerging SARS-CoV-2 variants, including KP.1.1 FLiRT and KP.3. The CDC predicts KP.3 will become the dominant variant soon.
June 14, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Invivyd's VYD222 demonstrates continued in vitro neutralization activity against emerging SARS-CoV-2 variants, including KP.1.1 FLiRT and KP.3. The CDC predicts KP.3 will become the dominant variant soon.
The continued neutralization activity of VYD222 against emerging variants, including those predicted to become dominant, is a positive development for Invivyd. This could lead to increased investor confidence and potential regulatory approvals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100